SCHEMBL25866749

SCHEMBL25866749

Cc1ccc(-c2ccc(C(=O)N=[N+]=[N-])c(C)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.61
RXFP1 Q9HBX9 1/20 0.48
ALDH1A1 P00352 1/20 0.48
RAB9A P51151 4/20 0.46
CASP3 P42574 4/20 0.45
NPC1 O15118 3/20 0.45
SENP8 Q96LD8 2/20 0.45
SENP7 Q9BQF6 2/20 0.45
SENP6 Q9GZR1 2/20 0.45
MAPT P10636 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
CA4 P22748 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ADORA3 P0DMS8 4/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353943 1.00 SMN1; SMN2 (0.61) SMN1; SMN2RXFP1ALDH1A1RAB9ACASP3
SCHEMBL25866684 0.72 SMN1; SMN2 (0.67) SMN1; SMN2RXFP1ALDH1A1RAB9ACASP3
SCHEMBL30242327 0.72 SMN1; SMN2 (0.67) SMN1; SMN2RXFP1ALDH1A1RAB9ACASP3
SCHEMBL28964278 0.71 SMN1; SMN2 (0.45) SMN1; SMN2RXFP1ALDH1A1RAB9ANPC1
SCHEMBL25866687 0.71 SMN1; SMN2 (0.65) SMN1; SMN2RXFP1ALDH1A1RAB9ACASP3
SCHEMBL13456261 0.70 KMT2A (0.35) SMN1; SMN2ALDH1A1RAB9ANPC1MAPT
SCHEMBL16161613 0.69 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1RAB9ANPC1MAPT
SCHEMBL28964279 0.69 SMN1; SMN2 (0.43) SMN1; SMN2RXFP1ALDH1A1RAB9ANPC1
SCHEMBL27598204 0.68 P2RX7 (0.50) SMN1; SMN2ALDH1A1RAB9ANPC1MAPT
SCHEMBL11319316 0.66 SMN1; SMN2 (0.73) SMN1; SMN2RXFP1ALDH1A1RAB9ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234926-A1 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER YEDITEPE UNIVERSITESI (TR) 2023-07-27 US disclosed
CN-115697981-A 2- (3- (2-methyl-6- (p-tolyl) pyridin-3-yl) ureido) benzenesulfonamides and derivatives as inhibitors of carbonic anhydrase IX for use in the treatment of cancer 耶迪特普大学 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234926-A1 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER CA9, CA6, CA2 SMN1; SMN2 4462/4885RXFP1 2706/4885ALDH1A1 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.